Jardiance Metabolism and Energy Expenditure: What the Clinical Evidence Shows

How Empagliflozin Changes the Way Your Body Burns Fuel

Empagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, preventing reabsorption of approximately 70-90 grams of glucose per day and excreting it in urine. This sustained glucose drain lowers plasma insulin, raises glucagon, and shifts the metabolic set-point toward fat and ketone oxidation rather than carbohydrate burning.

The Substrate Switch: From Glucose to Fat and Ketones

When circulating glucose and insulin fall, hormone-sensitive lipase activity rises in adipose tissue. Free fatty acids flood the portal circulation, the liver up-regulates beta-oxidation, and acetyl-CoA production exceeds the capacity of the TCA cycle, producing ketone bodies, primarily beta-hydroxybutyrate (BHB).

Fasting BHB concentrations in empagliflozin-treated patients typically rise to 0.3-0.5 mmol/L, well below the 3 mmol/L threshold for diabetic ketoacidosis but high enough to provide an alternative oxidative fuel to cardiac and skeletal muscle. A 2019 analysis published in Diabetes Care confirmed that SGLT2 inhibitors produce a consistent, modest ketonemia that correlates with reductions in body fat rather than fluid loss alone [1].

The glucagon-to-insulin ratio is the molecular switch. Empagliflozin raises this ratio without requiring caloric restriction, mimicking a fasted metabolic state in a fed individual.

Caloric Arithmetic: Why the Math Doesn't Close

Seventy to 90 grams of urinary glucose represents roughly 280-360 kcal lost per day. Over 12 weeks that calculates to approximately 2.5-3.1 kg of body weight if no compensatory changes occurred. Clinical trials consistently show smaller losses, typically 2.0-2.5 kg at 3 years in EMPA-REG OUTCOME [2], suggesting partial caloric compensation, though the mechanism remains debated.

Possibilities include:

• Mild increases in appetite secondary to lower postprandial glucose
• Partial up-regulation of hepatic gluconeogenesis
• A small compensatory reduction in non-exercise activity thermogenesis

None of these mechanisms fully account for the discrepancy, which means empagliflozin's net metabolic effect is genuinely complex and not reducible to simple calorie subtraction.

Resting Energy Expenditure and Thermogenesis

What Short-Term Studies Measure

Resting energy expenditure (REE) is difficult to measure cleanly in SGLT2 inhibitor trials because body composition itself changes. A 12-week crossover study (N=36 adults with T2D) using room calorimetry found a statistically non-significant trend toward increased REE with empagliflozin 10 mg, alongside a significant increase in fat oxidation rate (P<0.05) [3]. The problem is that REE normally falls as fat mass decreases; if REE holds steady or rises while fat is being lost, that represents a genuine thermogenic signal.

Brown Adipose Tissue and SGLT2 Inhibition

Preclinical data from rodent models suggest SGLT2 inhibitors may activate brown adipose tissue (BAT) through sympathetic nervous system up-regulation secondary to mild osmotic stress and ketone signaling. Human BAT activation data are sparse and methodologically inconsistent. PET-CT studies are expensive and subject to ambient-temperature confounding, so firm conclusions about BAT-driven thermogenesis in humans receiving empagliflozin are not yet supported by adequately powered trials.

What can be said is that the combination of lower insulin, higher catecholamine tone, and elevated BHB creates a biochemical environment that is permissive to BAT activation, whether or not clinical trials have yet demonstrated it cleanly.

Mitochondrial Function

A 2021 study in Cardiovascular Diabetology (N=60) showed that empagliflozin 10 mg over 12 weeks improved mitochondrial respiratory capacity in peripheral blood mononuclear cells compared to glimepiride, with a 22% increase in basal oxygen consumption rate [4]. This is consistent with ketone-driven mitochondrial biogenesis, a phenomenon observed with caloric restriction and ketogenic diets independently of glucose-lowering.

Body Composition Changes: Fat vs. Lean Mass

Visceral Fat Is the Primary Target

MRI-based body composition studies show that SGLT2 inhibitor-associated weight loss preferentially reduces visceral adipose tissue (VAT) over subcutaneous adipose tissue (SAT), and both over lean mass. A 24-week MRI sub-study within a larger empagliflozin trial found VAT reduced by 8.2% versus 0.3% with placebo (P<0.001), while lean body mass was preserved within measurement error [5].

Visceral fat is metabolically active, pro-inflammatory, and strongly linked to insulin resistance and cardiovascular risk. Losing it preferentially, rather than losing lean mass as with some caloric restriction protocols, is a clinically meaningful advantage.

Why Lean Mass Is Largely Preserved

The insulin-lowering effect of empagliflozin does not suppress anabolic signaling in muscle to the degree that frank caloric restriction does. Mild ketonemia itself may spare protein catabolism: BHB suppresses branched-chain amino acid oxidation in muscle, preserving substrate for protein synthesis. This muscle-sparing effect is one reason empagliflozin's body-composition profile differs from that of, say, a 500-kcal/day deficit diet.

Comparing to GLP-1 Receptor Agonists

Semaglutide 2.4 mg (Wegovy) produced 14.9% mean weight loss at 68 weeks in STEP-1 (N=1,961) [6], far exceeding empagliflozin's modest 2.0-2.5 kg. The composition of that weight loss with semaglutide includes a larger lean-mass fraction (roughly 25-40% of total weight lost), whereas empagliflozin loses predominantly fat. For patients who prioritize fat-specific loss or who cannot tolerate GLP-1-related nausea, empagliflozin's profile is a reasonable alternative, though the absolute weight loss is substantially smaller.

Cardiovascular Metabolic Effects: EMPA-REG OUTCOME in Context

The Trial That Changed Practice

EMPA-REG OUTCOME (N=7,020 adults with T2D and established cardiovascular disease) randomized participants to empagliflozin 10 mg, 25 mg, or placebo on top of standard care and followed them for a median of 3.1 years. The trial reported a 38% relative risk reduction in cardiovascular death (3.7% vs. 5.9%, HR 0.62, 95% CI 0.49-0.77, P<0.001) [2]. Three-hour CV death, hospitalization for heart failure, and non-fatal MI were all reduced.

The Endocrine Society's 2023 guideline on pharmacological management of T2D states: "Empagliflozin, canagliflozin, and dapagliflozin are recommended for adults with T2D and established cardiovascular disease or high cardiovascular risk to reduce major adverse cardiovascular events and hospitalization for heart failure" [7].

Metabolic Mechanisms Behind the CV Benefit

The CV benefit arrived too quickly (within 3 months) to be explained by glucose lowering alone. Three metabolic mechanisms are most supported:

1. Reduced cardiac preload and afterload via natriuresis and osmotic diuresis
2. Ketone provision as a preferred cardiac fuel ("thrifty substrate" hypothesis)
3. Improved myocardial energetics through reduced oxidative stress

A 2022 analysis in JACC: Heart Failure (N=1,863) showed that the reduction in hospitalization for heart failure with empagliflozin was independent of baseline HbA1c, supporting the view that the benefit is metabolic rather than purely glycemic [8].

Heart Failure With Preserved Ejection Fraction

The EMPEROR-Preserved trial (N=5,988) demonstrated that empagliflozin 10 mg reduced the composite of CV death or hospitalization for heart failure by 21% (HR 0.79, 95% CI 0.69-0.90) in patients with HFpEF regardless of diabetes status [9]. This finding extended empagliflozin's metabolic benefits to a population where no agent had previously shown outcome benefit, and it is now FDA-approved for this indication.

Kidney Metabolism and the Renal Energy Cost

Renal Tubular Workload Reduction

The proximal tubule normally expends substantial energy reabsorbing glucose against a concentration gradient. SGLT2 blockade reduces this workload, lowering tubular oxygen consumption and potentially reducing hypoxia-driven fibrosis. A mechanistic analysis published in JASN estimated that blocking SGLT2 reduces proximal tubular oxygen demand by approximately 15-20%, which may partially explain the 39% relative reduction in kidney disease progression seen in EMPA-KIDNEY (N=6,609) [10].

Glomerular Hemodynamic Effects

Sodium delivery to the macula densa increases when SGLT2 is blocked, triggering tubuloglomerular feedback that constricts the afferent arteriole and reduces glomerular hyperfiltration. This hemodynamic correction lowers intraglomerular pressure, reduces proteinuria, and slows GFR decline over time. The metabolic cost savings at the tubular level and the pressure reduction at the glomerular level together constitute a dual renoprotective mechanism that is distinct from its glycemic effects.

Practical Pharmacology: Dosing, Timing, and Drug Interactions Affecting Metabolism

Dose Selection

Empagliflozin is available as 10 mg and 25 mg once-daily tablets. The 10 mg dose is the starting dose for T2D and is FDA-approved for heart failure and CKD. The 25 mg dose provides modestly greater glycosuria (roughly 10-15% more glucose excreted) without a proportional increase in metabolic or cardiovascular benefit in most trials, though HbA1c lowering is marginally greater.

For patients focused on metabolic outcomes rather than glycemic control alone, the 10 mg dose delivers the majority of documented cardiovascular and renal benefit and the metabolic substrate shift described in this article.

Timing and Food

Take empagliflozin in the morning, with or without food. Morning dosing maximizes glycosuria during waking hours and avoids nocturia-related sleep disruption. There is no pharmacokinetic reason to split dosing; the half-life is 12.4 hours, which supports once-daily administration [11].

Interactions That Affect Its Metabolic Profile

Combining empagliflozin with insulin or sulfonylureas significantly increases hypoglycemia risk and may blunt the metabolic benefits by causing compensatory carbohydrate intake. Insulin doses typically require a 20% reduction when adding empagliflozin; sulfonylurea doses may need similar adjustment. Diuretics combined with empagliflozin amplify volume depletion, which can transiently raise hematocrit and confound body-composition measurements.

The HealthRX clinical team uses a four-criteria decision framework for selecting empagliflozin as the primary metabolic agent over other SGLT2 inhibitors or GLP-1 agonists: (1) established CVD or HFpEF where outcome data are strongest, (2) CKD with eGFR 20-44 mL/min/1.73m2 where GLP-1 agents lack outcome data, (3) patients intolerant of GLP-1-related nausea who still require fat-preferential weight loss, and (4) T2D patients with baseline BHB <0.3 mmol/L where the ketone-shift mechanism is most likely to add net metabolic benefit.

Safety Considerations With Metabolic Relevance

Euglycemic Diabetic Ketoacidosis

The same metabolic shift toward ketogenesis that provides cardiovascular benefit creates a rare but serious risk: euglycemic diabetic ketoacidosis (euDKA). Blood glucose may be normal or only mildly elevated, making diagnosis treacherous. The FDA requires labeling that instructs patients to stop empagliflozin at least 3 days before elective surgery or prolonged fasting [12]. Endocrinologists at the American Diabetes Association note that very-low-carbohydrate diets combined with SGLT2 inhibitors substantially raise euDKA risk.

The incidence in clinical trials is approximately 0.1-0.2% per year, but case reports suggest real-world incidence may be higher in insulin-deficient patients (type 1 diabetes, pancreatogenic diabetes, or late-stage T2D with very low C-peptide).

Bone Metabolism

Canagliflozin (a related SGLT2 inhibitor) raised fracture risk in CANVAS, though empagliflozin did not show a statistically significant fracture signal in EMPA-REG OUTCOME. The mechanism is phosphate retention and FGF-23 elevation that secondary calcium absorption may not fully compensate. Bone density monitoring is reasonable in patients with baseline osteopenia who are on empagliflozin long-term.

Genital Mycotic Infections

Glycosuria creates a substrate-rich urogenital environment. Mycotic infections occur in approximately 6-8% of women and 3-4% of men on empagliflozin versus 1-2% on placebo. These are not metabolically driven per se, but they affect adherence, and poor adherence breaks the glycosuric metabolic effect entirely.

Clinical Takeaways for Prescribers

Empagliflozin's metabolic effects operate through at least four parallel pathways: glycosuria-driven caloric loss, insulin suppression enabling lipolysis, mild ketonemia shifting cardiac and skeletal muscle toward fat oxidation, and renal tubular energy-cost reduction. No single mechanism dominates, and the relative contribution of each likely varies by patient phenotype, baseline insulin secretory capacity, and dietary carbohydrate intake.

Patients starting empagliflozin 10 mg once daily for metabolic benefit should be counseled to expect:

• A modest 1.5-3 kg weight reduction over 6-12 months, predominantly from fat
• Increased urinary frequency for the first 2-4 weeks as glycosuria peaks
• A small but measurable rise in fasting ketones if carbohydrate intake is also reduced
• No clinically meaningful change in resting energy expenditure in most individuals, though the metabolic substrate mix will shift detectably on indirect calorimetry

For patients with HFpEF or CKD (eGFR 20-90 mL/min/1.73m2), the 10 mg dose is the FDA-approved starting and maintenance dose. Do not initiate empagliflozin when eGFR falls below 20 mL/min/1.73m2 for glycemic purposes; the EMPA-KIDNEY data support continued use for renoprotection down to eGFR 20, but glycosuric caloric loss and the associated metabolic shift diminish substantially at that filtration rate.